WO2004087149A1 - 医薬組成物 - Google Patents
医薬組成物 Download PDFInfo
- Publication number
- WO2004087149A1 WO2004087149A1 PCT/JP2004/004623 JP2004004623W WO2004087149A1 WO 2004087149 A1 WO2004087149 A1 WO 2004087149A1 JP 2004004623 W JP2004004623 W JP 2004004623W WO 2004087149 A1 WO2004087149 A1 WO 2004087149A1
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- lung disease
- disease
- group
- eosinophilic pneumonia
- asthma
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
- C07D405/06—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
- A61K31/443—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with oxygen as a ring hetero atom
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
- A61K31/575—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of three or more carbon atoms, e.g. cholane, cholestane, ergosterol, sitosterol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
- A61K31/58—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids containing heterocyclic rings, e.g. danazol, stanozolol, pancuronium or digitogenin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/06—Antiasthmatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
Definitions
- the present invention relates to a pharmaceutical composition containing a phosphodiesterase IV inhibitor (PDE-IV inhibitor) and a steroid.
- PDE-IV inhibitor phosphodiesterase IV inhibitor
- COPD chronic obstructive pulmonary disease
- An object of the present invention is 7- [2- (3, 5-dichloro-one 4 one-pyridyl) -1 one year old Kisoe chill] -4-methoxy-over-spiro [1, 3 Penzojiokiso Ichiru one 2, 1 5 Shikurobe And a pharmacologically acceptable salt thereof, and a steroid agent.
- the present invention relates to the following (1) to (31).
- the steroid agent is a compound selected from the group consisting of prednisolone, methylprednisolone, prednisone, dexamethasone, flutidinzone propionate, beclomethasone propionate, budesonide, flunisolide, and momesone furoate ( 3)
- the therapeutic and / or prophylactic agent for the described lung disease is a compound selected from the group consisting of prednisolone, methylprednisolone, prednisone, dexamethasone, flutidinzone propionate, beclomethasone propionate, budesonide, flunisolide, and momesone furoate ( 3)
- the therapeutic and / or prophylactic agent for the described lung disease is a compound selected from the group consisting of prednisolone, methylprednisolone, prednisone, dexamethasone, flutidinzone propionate, beclomethas
- lung disease from COPD, emphysema, chronic bronchitis, chronic acute respiratory distress syndrome (ARDS), acute lung injury (ALI), asthma, bronchial asthma, acute eosinophilic pneumonia and chronic eosinophilic pneumonia
- ARDS chronic acute respiratory distress syndrome
- ALI acute lung injury
- asthma bronchial asthma
- acute eosinophilic pneumonia chronic eosinophilic pneumonia
- chronic eosinophilic pneumonia chronic eosinophilic pneumonia
- the agent for treating and / or preventing lung disease according to (3) or (4), which is a disease selected from the group consisting of:
- the pulmonary disease is a disease selected from the group consisting of asthma, bronchial asthma, acute eosinophilic pneumonia and chronic eosinophilic pneumonia; Or prophylactic agent.
- Equation (I) In represented by 7- [2- (3, 5-dichloro-one 4 one-pyridyl) one 1-Okisoechiru] - 4-methoxy-over-spiro [1, 3 Benzojiokiso one route 2, 1 5 - Shikuropen Yun] or a A kit comprising: a first component containing a pharmacologically acceptable salt; and (b) a second component containing a steroid agent.
- the steroid is a compound selected from the group consisting of prednisolone, methylprednisolone, prednisone, dexamethasone, flutidinzone propionate, beclomethasone propionate, budezonide, flunisolide, and momesone furoate (8 ) Described kit.
- kits for treating and / or preventing lung disease comprising: a first component containing a pharmacologically acceptable salt; and (b) a second component containing a steroid agent.
- the steroid is a compound selected from the group consisting of prednisolone, methylprednisolone, prednisone, dexamethasone, flutidinzone propionate, beclomethasone propionate, budesonide, flunisolide, and momesone furoate ( 10)
- the lung disease is a disease selected from the group consisting of COPD, emphysema, chronic bronchitis, ARDS, ALI, asthma, bronchial asthma, acute eosinophilic pneumonia and chronic eosinophilic pneumonia (10) or (11)
- the pulmonary disease is a disease selected from the group consisting of asthma, bronchial asthma, acute eosinophilic pneumonia and chronic eosinophilic pneumonia; / Or prevention kit.
- the compound in which the steroid agent is selected from the group consisting of prednisolone, methylprednisolone, prednisone, dexamethasone, flutizozone propionate, beclomethasone propionate, budesonide, flunizolide, and momezono furoate.
- 7- [2- (3,5-Dichloro-4-pyridyl) —1_oxo.Sethyl] —4-Methoxyspiro [1,3-benzodioxol-1,2,1, Pentane] or a pharmacologically acceptable salt thereof.
- Formula (I) for simultaneous or separate administration of steroids 7- [2- (3,5-dichloro-1-4-pyridyl) -1-1-oxoethyl] -1,4-methoxy-1-spiro [1,3-benzodioxo-1-ru 2,1,1-cyclopentane] or its pharmacology A pharmaceutical composition comprising a chemically acceptable salt as an active ingredient.
- the steroid agent is a compound selected from the group consisting of prednisolone, methylprednisolone, prednisone, dexamethasone, flutidinzone propionate, beclomethasone propionate, budesonide, flunisolide, and momesone furoate.
- a method for treating and preventing or preventing lung disease which comprises administering.
- the steroid agent is a compound selected from the group consisting of prednisolone, methylprednisolone, prednisone, dexamethasone, flutizozone propionate, ⁇ clomethasone propionate, budesonide, flunizolide, and momesone furoate.
- lung disease is C0PD, emphysema, chronic bronchitis, ARDS, ALI, asthma
- the pulmonary disease is a disease selected from the group consisting of asthma, bronchial asthma, acute eosinophilic pneumonia and chronic eosinophilic pneumonia; Or preventive measures.
- the lung disease is a disease selected from the group consisting of COPD, emphysema, chronic bronchitis, ARDS, ALI, asthma, bronchial asthma, acute eosinophilic pneumonia and chronic eosinophilic pneumonia (24 ) A method for treating and / or preventing a lung disease according to the above.
- lung disease is a disease selected from the group consisting of i-breath, bronchial asthma, acute eosinophilic pneumonia and chronic eosinophilic pneumonia.
- the lung disease is a disease selected from the group consisting of COPD, emphysema, chronic bronchitis, ARDS, ALI, asthma, bronchial asthma, acute eosinophilic pneumonia and chronic eosinophilic pneumonia (28) Use of. '.
- lung disease is a disease selected from the group consisting of asthma, bronchial asthma, acute eosinophilic pneumonia and chronic eosinophilic pneumonia.
- Pharmaceutically acceptable salts of compound (I) include pharmacologically acceptable acid addition salts, metal salts, ammonium salts, organic amine addition salts, amino acid addition salts and the like.
- Pharmaceutically acceptable acid addition salts of compound (I) include inorganic acid salts such as hydrochloride, sulfate, hydrobromide, nitrate and phosphate, acetate, mesylate, and succinate Organic salts such as acid salts, maleates, fumarates, citrates, and tartrates; pharmacologically acceptable metal salts include alkali metal salts such as sodium salts and potassium salts; Examples include alkaline earth metal salts such as magnesium salts and calcium salts, aluminum salts, zinc salts, and the like.Pharmacologically acceptable ammonium salts include salts such as ammonium salts and tetramethyl ammonium salts.
- Examples of pharmacologically acceptable organic amine addition salts include addition salts such as morpholine and piperidine, and pharmacologically acceptable amino acid addition salts include glycine and Et two Ruaranin, lysine, Asuparagin acid addition salts such as glutamic acid.
- Compound (I) can be produced by the method described in WO 96/36624.
- Compound (I) may exist in stereoisomers such as tautomers, and the pharmaceutical composition of the present invention, a therapeutic and / or prophylactic agent for pulmonary disease, a kit, a therapeutic agent for pulmonary disease and / or For a prophylactic kit and a method for treating and / or preventing lung disease, all possible isomers, including these, and mixtures thereof can be used.
- Compound (I) of the present invention includes Including all possible isomers and mixtures thereof.
- the compound (I) may be dissolved or suspended in an appropriate solvent, and isolated and purified by adding an acid or a base when the compound (I) is obtained in a free form.
- Compound (I) and a pharmaceutically acceptable salt thereof may be present in the form of adducts with water or various solvents, and these adducts are also present in the pharmaceutical composition of the present invention, A therapeutic and / or prophylactic agent, a kit for treating and / or preventing lung disease and a method for treating and / or preventing lung disease, and a compound of the present invention.
- steroids As steroids, steroid derivatives having a reducing action such as cytokines, mast cells, eosinophils, etc. which are inflammation-causing substances, an inhibitory action on inflammatory cell migration or activation, or pharmacologically acceptable steroids are acceptable. Any salt may be used.
- prednisolone represented by the formula (A) (predni sol one)
- Methylprednisolone represented by the formula (B)
- Methylprednisolone succinate represented by the formula (E)
- Prednisolones such as
- Cortisone acetate represented by the formula (L) (cortisone one ac et at e) s Hydrocortisone represented by the formula (M), hydrocortisone succinate represented by the formula (N)
- conoretisones such as (f ludro colon is one ac et at e),
- Triamcinolone (t riamcino lone) represented by the formula (V)
- Halopredone acetate (ha 1 opredo ne acetate at e) and the like, preferably prednisolone, methylprednisolone, prednisone, dexamethasone, flutizozone propionate, ⁇ glomesone diprovionate, budesonide, momesone furocarbone And so on. These may be used alone or in combination.
- These steroids include pharmacologically acceptable salts (the pharmacologically acceptable salts include the salts exemplified as the pharmacologically acceptable salts of the compound (I)). Or a hydrate thereof, the pharmaceutical composition of the present invention, an agent for treating and / or preventing lung disease, a kit, a kit for treating and / or preventing lung disease, and a lung disease These can also be used to treat and / or prevent You.
- some of these steroids have one or more asymmetric carbons and the like and two or more stereoisomers, but the pharmaceutical composition of the present invention, the treatment of lung diseases and Use all possible isomers, including these, and mixtures thereof in prophylactic agents, kits, kits for treating and / or preventing lung disease and methods for treating and / or preventing lung disease Can be.
- the pharmaceutical composition and kit of the present invention can be used, for example, for the treatment of pulmonary diseases, and more specifically, COPD, emphysema, chronic bronchitis, ARDS, ALI, asthma, bronchial asthma, acute It can be used to treat pulmonary diseases such as eosinophilic pneumonia, chronic eosinophilic pneumonia, interstitial pneumonia, and pulmonary fibrosis. .
- the compound (I) or a pharmacologically acceptable salt thereof and the steroid agent used in the pharmaceutical composition of the present invention or the agent for treating and / or preventing lung disease contain these active ingredients.
- it can be used or administered as a single agent (mixture) or a combination of a plurality of agents. Among them, a combination of two or more agents is preferable.
- When used or administered as a combination of a plurality of preparations they can be used or administered simultaneously or separately at an interval.
- These preparations are preferably used in the form of tablets, injections, or inhalants such as dry powder and aerosol.
- the dose ratio (weight / weight) of compound (I) or a pharmacologically acceptable salt thereof to a steroid can be adjusted as appropriate in accordance with the combination of the steroid used and the potency of the steroid. Good, but specifically, for example, about 1/50 (compound (I) or a pharmaceutically acceptable salt / steroid agent thereof) to 50,000 / 1, preferably 1Z30 to 10000/1, more preferably 1/20. 50005000/1, more preferably a ratio between 1Z10 ⁇ : L 000/1.
- a first component containing compound (I) or a pharmaceutically acceptable salt thereof, and (b) a second component containing a steroid agent are separately formulated as described above and prepared as kits, and each component is used simultaneously or at the same time with the same subject for the same subject.
- -It can be administered by a route or by different routes.
- the kit includes, for example, components that are contents caused by external temperature or light during storage. Material and shape are not particularly limited as long as denaturation and elution of chemical components from the container are not observed.
- the container consists of two or more containers (for example, vials and bags) and the contents.
- a component in which the first component and the second 'component have a form that can be administered via separate routes (eg, a tube) or the same route is used.
- Specific examples include kits for tablets, injections, inhalants, and the like. Inhalation kits can be combined with commonly used metered dose inhalers (MDIs), powder inhalers, etc. to provide one or more for the administration of the first and second components. May be included.
- MDIs metered dose inhalers
- the above-mentioned dry powder inhaler and the like may be included.
- the kit also includes a multi-dose dry powder inhaler (MDPI) in which the drug storage portion includes the drug storage portion containing the first component dry powder and the drug storage portion containing the second component dry powder.
- MDPI multi-dose dry powder inhaler
- the method for treating and / or preventing a lung disease of the present invention comprises the use of the compound (I) used in the above-mentioned pharmaceutical composition or an agent for treating and / or preventing a lung disease or a pharmaceutically acceptable salt thereof. It can be carried out in the same manner as the use or administration method of the salt and the steroid, that is, the compound (I) or a pharmacologically acceptable salt thereof and the steroid are formulated so as to contain the respective active ingredients. It can be carried out as a single agent or as a combination of a plurality of preparations, preferably by administering a combination of two or more preparations. When a plurality of preparations are administered in combination, these preparations can be administered simultaneously or separately at an interval, and can also be administered using a kit as described above.
- BALB / c mouse male, 7 weeks old, Charles Nippon, Japan was intraperitoneally administered with 3 mL / vol% of thioglycolate 1 mL, and the peritoneal exudate was collected 72 hours later to prepare peritoneal exudate cells .
- the test dagger was 1 volume / volume% RPMI 1640 dimethyl sulfoxide
- DMSO Dissolve in (DMSO) solution
- LPS test compound added group
- a group to which DMSO-RPMI solution was added at the same time as LPS is referred to as a solvent added group
- a group to which only DMSO-RPMI solution was added is referred to as a non-added group.
- the inhibition rate (%) of TNF-producing is calculated according to the following formula.
- Test Example 2 Inhibitory effect of combined administration of compound (I) and steroid on rat antigen-induced airway eosinophil and neutrophil infiltration
- BN rat (Charles Riva Japan) was used.
- the rats were housed in a breeding room with room temperature 19-25 °, humidity 30-70%, 12 hours a day (7 am-7 pm) in aluminum cages with 5-6 rats each. They were fed with free access to feed and water.
- a preparation consisting of 5 mg of lactose (manufactured by DVM) with respect to 1 mg of compound (I) was prepared.
- Azur Co., Ltd. was prepared by suspending the above formulation so that the concentration of compound (I) was 150 ⁇ g / h.
- lactose and budesonide are suspended in an aqueous 0.125% w / v tyloxapol solution so that the concentrations thereof become 750 ⁇ g / mL and 50 / g / mL, respectively, to give a suspension for budesonide administration.
- budesonide and the compound prepared above were added such that the concentrations of pdesozide and compound (I) in a 0.125% w / v tyloxapol aqueous solution were 50 ⁇ g / mL and 150 g / mL, respectively.
- (I) The lactose preparation was suspended to prepare a combined administration suspension. Lactose dissolved in a 0.125% by weight / volume aqueous tyloxapol solution at a concentration of 7.5 mg / mL was used as a solvent for administration.
- ovalbumin ovalbumin
- aluminum hydroxide manufactured by Wako Pure Chemical Industries
- Active sensitization was performed by intraperitoneally administering 0.5 mL of a pertussis killed bacterial suspension (2 ⁇ 10 1 Q pieces Z 1 mL physiological saline, manufactured by Kaken Pharmaceutical Co., Ltd.). 14 days after active sensitization, put a rat in a plastic chamber (30x50x30 cm) and spray 1% w / v OVA saline for 10 minutes with an ultrasonic nebulizer (Omron) to spray antigen.
- OVA ovalbumin
- Al hydroxide manufactured by Wako Pure Chemical Industries
- Bronchoalveolar lavage (BAL) was performed 24 hours after spraying 1% w / v OVA saline or saline. Rats were anesthetized by intraperitoneal injection of pentobarbi (Dai Nippon Pharmaceutical Co., Ltd.), and the alveolar cavity was washed with a saline solution through a tracheal force neurula to obtain bronchoalveolar lavage fluid (BALF).
- BALF bronchoalveolar lavage fluid
- the total white blood cell count in BALF was measured using an automatic blood cell counter Yuichi (Nihon Kohden).
- a smear of the cells was prepared, stained with Giemsa, observed under an optical microscope, and the number of eosinophils and neutrophils was counted, and the ratio of each was calculated.
- Eosinophil and neutrophil counts were calculated by multiplying the total leukocyte count by the cell count ratio of each cell.
- the eosinophil count in BALF and the inhibition rate (%) against the increase in neutrophil count were calculated as follows.
- Neutrophil count inhibition rate (%) X100 Neutrophil count in vehicle-administered group-Neutrophil count in saline-administered group
- Table 1 shows the results for the increase in the number of eosinophils
- Table 2 shows the results for the increase in the number of neutrophils.
- each value of the number of eosinophils and the number of neutrophils is shown by an average value standard error.
- the number of neutrophils in BALF increased to 21 times the number of eosinophils in BALF in the saline group by antigen exposure.
- Administration of compound (I) (30 ⁇ g / animal) and pudesonide (10 ⁇ g / animal) alone had no significant effect on neutrophil count in BALF
- an effect of suppressing the increase in the number of neutrophils was confirmed by the combined administration of compound (I) and budezonide.
- Asthma and bronchial asthma are diseases characterized by eosinophilic airway inflammation [Cl in. Exp. Alli., Vol. 32, p. 162 (2002 )], It is known that in patients with asthma and bronchial asthma, marked eosinophil infiltration into lung tissue and a marked increase in the number of eosinophils in BALF are observed. On the other hand, it is obtained from patients with COPD; many neutrophils are found in BALF and sputum, and patients with higher neutrophil count in sputum or bronchial mucosa have worse airway obstruction [American Review ⁇ Ob ⁇ Respiratory Digits (Am. Rev.
- the combined administration of compound (I) or a pharmacologically acceptable salt thereof and a steroid agent can be used for asthma, bronchial asthma, acute eosinophilic inflammation, chronic eosinophilic inflammation, It is considered to be effective for treating and / or preventing lung diseases such as COPD.
- steroids show strong anti-inflammatory effects and are excellent drugs for treating lung diseases such as asthma, bronchial asthma, and COPD, but have adverse effects on oropharynx, bone metabolism, etc. It has been reported to cause serious side effects such as growth impairment in the animal ['American Journal Ops Resilitory and Critical Canole Care I Medicin' (Am. J. Resir Crit) Car e Med.), Volume 157, S1 page (1998)] 0
- the results of the above test show that the combination of compound (I) or a pharmacologically acceptable salt thereof and steroids can be used to determine the dose of steroids conventionally used in the treatment of lung diseases such as asthma, bronchial asthma and COPD. Can be reduced. That is, the pharmaceutical composition, the therapeutic and / or preventive agent for lung disease, the kit or the kit for treating and / or preventing lung disease of the present invention can be used for the treatment of lung diseases such as asthma, bronchial asthma, and COPD. It is expected that the dosage of the steroid agent used can be reduced, and that not only the effect obtained by the conventional single agent but also the above-mentioned side effects can be reduced.
- the pharmaceutical composition used for the present invention or the agent for treating and / or preventing lung disease comprises a compound (I) or a pharmacologically acceptable salt thereof and a steroid or an active ingredient thereof.
- the therapeutic and / or prophylactic agent for a substance or lung disease is preferably in a unit dosage form suitable for oral administration such as tablets or parenteral administration such as inhalants and injections. When used or administered as a combination of a plurality of preparations, they can be used or administered simultaneously or separately at an interval.
- Each of these preparations contains, in addition to the active ingredient, a pharmaceutically acceptable diluent, excipient, disintegrant, lubricant, binder, surfactant, water, physiological saline, vegetable oil solubilizer. It can be prepared by an ordinary method using an isotonic agent, a preservative, an antioxidant and the like as appropriate.
- excipients such as lactose, disintegrants such as starch, lubricants such as magnesium stearate, binders such as hydroxypropylcellulose, surfactants such as fatty acid esters, glycerin and the like
- a plasticizer or the like may be used according to a conventional method.
- water physiological saline
- vegetable oils such as soybean oil
- various solvents such as soybean oil
- solubilizers such as soybean oil
- isotonic agents such as preservatives, antioxidants and the like
- Inhalants are also prepared by making the active ingredient into a powder or a liquid, compounding it in an inhalation propellant or carrier, and filling into an appropriate inhalation container.
- a conventional mechanical powder inhaler can be used
- an inhaler such as a nebulizer
- conventionally known inhalation propellants can be widely used, and CFC-11, CFC-12, CFC-11, CFC-12, CFC-11, CFC-11, CFC-11 1 1 2 3, 1 CFC 1 4 2c, 1 CFC 1 3 4a, 1 CFC
- the dose and frequency of administration will depend on the dosage form, patient Depending on the age, body weight, symptoms, etc., the daily dose of Compound (I) or its pharmacologically acceptable salts and steroids is usually less than Preferably it is administered in doses. '
- compound (I) or a pharmacologically acceptable salt thereof and a steroid may be administered in an amount of 0.01 to 1000 mg and 0.01 to 100 Omg per adult, respectively.
- Compound (I) or a pharmacologically acceptable salt thereof and a steroid compound are administered to an adult in an amount of lg to lO Omg and 0.01 mg, respectively.
- the dose and frequency of administration are determined by the dosage form, age and weight of the patient. Although it varies depending on the condition and the like, it is preferable to prepare and use or administer as a single preparation at each dose when used or administered as a combination of a plurality of the above-mentioned preparations.
- a tablet having the following composition is prepared by a conventional method.
- Compound (I) 40 g s lactose 286.8 g and potato starch 60 g are mixed, and 12 Og of a 10% aqueous solution of hydroxypropyl cell mouth is added thereto. This mixture is kneaded by a conventional method, granulated, dried, and then sized to obtain granules for tableting. 1.2 g of magnesium stearate was mixed with the calorie, and the mixture was compressed with a tablet machine (RT-15 type, manufactured by Kikusui) having an 8 mm diameter punch. Is obtained.
- Prescription compound (I) 20 mg
- a tablet having the following composition is prepared by a conventional method. 40 g of prednisolone, 286.8 g of lactose and 6.0 g of potato starch are mixed, and 120 g of a 10% aqueous solution of hydroxypropyl cellulose is added thereto. This mixture is kneaded by a conventional method, granulated, dried, and then sized to obtain granules for tableting. To this, 1.2 g of magnesium stearate was mixed calorically, and the mixture was tableted with a tableting machine (RT-15 type, manufactured by Kikusui) having an 8 mm diameter punch, and tablets (2 Omg of active ingredient per tablet) were pressed. Is obtained.
- RT-15 type manufactured by Kikusui
- Example 3 Tablet (compound (I) and prednisolone monotherapy) ''
- a tablet having the following composition is prepared by a conventional method.
- Compound (I) 40 g Prednisolone 40 g, lactose 246.8 g, and potato starch 60 g are mixed, and 120 g of a 10% aqueous solution of hydroxypropyl cellulose is added thereto. This mixture is kneaded, granulated and dried by a conventional method, and then sized to obtain granules for tableting. To this, 1.2 g of magnesium stearate was added and mixed, and the mixture was tableted using a tableting machine equipped with an 8 mm diameter punch (manufactured by Kikuhisa Co., Ltd .: RT-15 type). Per tablet containing 2 Omg of compound (I) and 2 Omg of prednisolone). Prescription compound (e) 20 mg
- An injection having the following composition is prepared by a conventional method.
- Compound (I) lg is dissolved in purified soybean oil, and 12 g of purified egg yolk lecithin and 25 g of glycerin for injection are added. This mixture is kneaded and emulsified in a conventional manner with distilled water for injection to 1000 mL. The resulting dispersion is aseptically filtered using a 0.2-m disposable membrane filter, and then aseptically filled into glass vials in 2 mL increments. Containing) is obtained.
- An injection having the following composition is prepared by a conventional method. Dissolve 1 g of methylprednisolone in refined soybean oil and add 12 g of purified egg yolk lecithin and 25 g of glycerin for injection. This mixture is kneaded and emulsified with distilled water for injection to 100 OmL by a conventional method. The resulting dispersion is aseptically filtered using a 0.2 m disposable membrane filter, and aseptically filled into glass vials in 2 mL increments. Injection (containing 2 mg of active ingredient per vial) Get. Prescription Methylprednisolone 2 mg
- An injection having the following composition is prepared by a conventional method.
- Compound (I) lg and 1 g of methyl prednisolone are dissolved in purified soybean oil, and 12 g of purified egg yolk lecithin and 25 g of glycerin for injection are added. This mixture is adjusted to 100 OmL with distilled water for injection and kneaded and emulsified by a conventional method.
- the resulting dispersion is aseptically filtered using a 0.2-m disposable membrane filter, and aseptically filled into glass vials in a volume of 2 mL each.
- a dry powder inhalant having the following composition by the usual method.
- the compound (I) is pulverized using a jet mill (volume average particle diameter: 5 to 20 m).
- the pulverized compound (I) obtained and lactose (Pharmatose 325M; registered trademark, manufactured by DMV) are mixed at a weight ratio of 1: 5 to obtain a dry powder preparation.
- the formulation can be administered with a conventional dry powder inhaler.
- Formulation Compound (I) 16.7 mg
- Example 8 Dry powder inhalant (budesonide)
- a dry powder inhalant having the following composition by the usual method. Using a jet mill, pudesonide is pulverized (volume average particle size: both 5 to 20 m). The resulting pulverized budesonide and lactose (Pharmaose 325M; registered trademark, manufactured by DMV) are mixed at a weight ratio of 1:10 to obtain a dry powder preparation. The formulation can be administered with a conventional dry pad inhaler.
- Example 9 Dry powder inhalant (compound (I) and budesonide alone)
- the present invention 7- [2- (3 5-dichloro 4-pyridyl) Single 1- Okisoechi Le 1 4-methoxy-one-spiro [1 3- Benzojiokiso one route 2, 1 5 - Shikuropen Tan] or a pharmaceutically And a pharmaceutical composition containing a pharmaceutically acceptable salt and a steroid agent.
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Organic Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Engineering & Computer Science (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Pulmonology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
Abstract
Description
Claims
Priority Applications (4)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US10/550,208 US20060199789A1 (en) | 2003-03-31 | 2004-03-31 | medical composition |
EP04724784A EP1616569A1 (en) | 2003-03-31 | 2004-03-31 | Medicinal composition |
JP2005504268A JPWO2004087149A1 (ja) | 2003-03-31 | 2004-03-31 | 医薬組成物 |
CA002520577A CA2520577A1 (en) | 2003-03-31 | 2004-03-31 | Pharmaceutical composition |
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
JP2003094508 | 2003-03-31 | ||
JP2003-094508 | 2003-03-31 |
Publications (1)
Publication Number | Publication Date |
---|---|
WO2004087149A1 true WO2004087149A1 (ja) | 2004-10-14 |
Family
ID=33127394
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/JP2004/004623 WO2004087149A1 (ja) | 2003-03-31 | 2004-03-31 | 医薬組成物 |
Country Status (6)
Country | Link |
---|---|
US (1) | US20060199789A1 (ja) |
EP (1) | EP1616569A1 (ja) |
JP (1) | JPWO2004087149A1 (ja) |
CN (1) | CN1767828A (ja) |
CA (1) | CA2520577A1 (ja) |
WO (1) | WO2004087149A1 (ja) |
Citations (6)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO1996036624A1 (fr) * | 1995-05-19 | 1996-11-21 | Kyowa Hakko Kogyo Co., Ltd. | Composes heterocycliques contenant de l'oxygene |
WO2001032127A2 (en) * | 1999-11-02 | 2001-05-10 | Smithkline Beecham Corporation | Method and compositions for treating pulmonary diseases |
WO2001057036A1 (en) * | 2000-01-31 | 2001-08-09 | Pfizer Products Inc. | Nicotinamide benzofused-heterocyclyl derivatives useful as selective inhibitors of pde4 isozymes |
WO2001064639A2 (en) * | 2000-03-02 | 2001-09-07 | Merck Frosst Canada & Co. | Pde iv inhibiting amides, compositions and pharmaceutical use |
WO2003066044A1 (de) * | 2002-02-08 | 2003-08-14 | Kyowa Hakko Kogyo Co., Ltd. | Neue arzneimittelkompositionen enthaltend neben anticholinergika heterocyclische verbindungen |
WO2004005276A1 (ja) * | 2002-07-03 | 2004-01-15 | Kyowa Hakko Kogyo Co., Ltd. | 1,3−ベンゾジオキソール−2−スピロシクロアルカン誘導体の製造法 |
Family Cites Families (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US6514996B2 (en) * | 1995-05-19 | 2003-02-04 | Kyowa Hakko Kogyo Co., Ltd. | Derivatives of benzofuran or benzodioxole |
-
2004
- 2004-03-31 JP JP2005504268A patent/JPWO2004087149A1/ja not_active Withdrawn
- 2004-03-31 CA CA002520577A patent/CA2520577A1/en not_active Abandoned
- 2004-03-31 CN CNA2004800089202A patent/CN1767828A/zh active Pending
- 2004-03-31 WO PCT/JP2004/004623 patent/WO2004087149A1/ja not_active Application Discontinuation
- 2004-03-31 EP EP04724784A patent/EP1616569A1/en not_active Withdrawn
- 2004-03-31 US US10/550,208 patent/US20060199789A1/en not_active Abandoned
Patent Citations (6)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO1996036624A1 (fr) * | 1995-05-19 | 1996-11-21 | Kyowa Hakko Kogyo Co., Ltd. | Composes heterocycliques contenant de l'oxygene |
WO2001032127A2 (en) * | 1999-11-02 | 2001-05-10 | Smithkline Beecham Corporation | Method and compositions for treating pulmonary diseases |
WO2001057036A1 (en) * | 2000-01-31 | 2001-08-09 | Pfizer Products Inc. | Nicotinamide benzofused-heterocyclyl derivatives useful as selective inhibitors of pde4 isozymes |
WO2001064639A2 (en) * | 2000-03-02 | 2001-09-07 | Merck Frosst Canada & Co. | Pde iv inhibiting amides, compositions and pharmaceutical use |
WO2003066044A1 (de) * | 2002-02-08 | 2003-08-14 | Kyowa Hakko Kogyo Co., Ltd. | Neue arzneimittelkompositionen enthaltend neben anticholinergika heterocyclische verbindungen |
WO2004005276A1 (ja) * | 2002-07-03 | 2004-01-15 | Kyowa Hakko Kogyo Co., Ltd. | 1,3−ベンゾジオキソール−2−スピロシクロアルカン誘導体の製造法 |
Non-Patent Citations (1)
Title |
---|
YOSHIYAMA YUJI ET AL: "PHARMACIA", JIKAN CHIRYO E MUKETE, vol. 34, no. 6, 1998, pages 573 - 578, XP002981593 * |
Also Published As
Publication number | Publication date |
---|---|
JPWO2004087149A1 (ja) | 2006-06-29 |
EP1616569A1 (en) | 2006-01-18 |
CA2520577A1 (en) | 2004-10-14 |
CN1767828A (zh) | 2006-05-03 |
US20060199789A1 (en) | 2006-09-07 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
JP5579368B2 (ja) | 慢性呼吸器疾患を治療するためのメチルキサンチン化合物とステロイドの組み合わせ | |
US20080027034A1 (en) | Ciclesonide and Syk Inhibitor Combination and Method of Use Thereof | |
CA2579017A1 (en) | Roflumilast and syk inhibitor combination and methods of use thereof | |
KR20180128390A (ko) | 인돌리논 화합물과 섬유성 질환의 치료에서 이의 용도 | |
CA2948574A1 (en) | Combinations of formoterol and budesonide for the treatment of copd | |
CA2827299A1 (en) | Liquid propellant-free formulation comprising an antimuscarinic drug | |
KR101778814B1 (ko) | 포모테롤 및 베클로메타손 디프로피오네이트의 약학적 에어로졸 제제 | |
US20030064031A1 (en) | Use of a combination of compounds in a dry powder inhaler | |
US20070287689A1 (en) | Therapeutic And/Or Preventive Agents For Chronic Skin Diseases | |
WO2004087149A1 (ja) | 医薬組成物 | |
US20070134165A1 (en) | Use of Ciclesonide for the Treatment of Respiratory Disease in a Smoking Patient | |
US20140080846A1 (en) | Method of treating orphan respiratry diseases using doxofylline | |
AU2013368298B2 (en) | Methods and compositions for administration of oxybutynin | |
WO2004087150A1 (ja) | 医薬組成物 | |
Linne-Geyer et al. | P291 In-use stability of aclidinium bromide 400 μg/formoterol fumarate dihydrate 12 μg inhalation powder in a dry powder inhaler | |
JP2005047835A (ja) | 医薬組成物 | |
WO2004087148A9 (ja) | 肺疾患の治療および/または予防剤 | |
WO2004087151A1 (ja) | 医薬組成物 | |
EP4209219A1 (en) | Combination of budesonide and 5-amino-2,3-dihydro-1,4-phtalazinedione | |
EP4346789A1 (en) | Capsaicin derivatives in the treatment of idiopathic pulmonary fibrosis | |
WO2005056009A1 (ja) | 肺疾患治療剤 | |
NZ579186A (en) | A carbostyril derivative with probucol for treating chronic obstructive pulmonary disease | |
WO2004087147A1 (ja) | 肺疾患の治療および/または予防剤 | |
JP2007008815A (ja) | N−(ベンゾイル)アミノ酸誘導体を有効成分とする呼吸器疾患治療剤 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
AK | Designated states |
Kind code of ref document: A1 Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BW BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EC EE EG ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NA NI NO NZ OM PG PH PL PT RO RU SC SD SE SG SK SL SY TJ TM TN TR TT TZ UA UG US UZ VC VN YU ZA ZM ZW |
|
AL | Designated countries for regional patents |
Kind code of ref document: A1 Designated state(s): BW GH GM KE LS MW MZ SD SL SZ TZ UG ZM ZW AM AZ BY KG KZ MD RU TJ TM AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IT LU MC NL PL PT RO SE SI SK TR BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG |
|
121 | Ep: the epo has been informed by wipo that ep was designated in this application | ||
WWE | Wipo information: entry into national phase |
Ref document number: 2005504268 Country of ref document: JP |
|
WWE | Wipo information: entry into national phase |
Ref document number: 10550208 Country of ref document: US |
|
WWE | Wipo information: entry into national phase |
Ref document number: 2520577 Country of ref document: CA |
|
WWE | Wipo information: entry into national phase |
Ref document number: 20048089202 Country of ref document: CN |
|
WWE | Wipo information: entry into national phase |
Ref document number: 2004724784 Country of ref document: EP |
|
WWP | Wipo information: published in national office |
Ref document number: 2004724784 Country of ref document: EP |
|
WWP | Wipo information: published in national office |
Ref document number: 10550208 Country of ref document: US |
|
WWW | Wipo information: withdrawn in national office |
Ref document number: 2004724784 Country of ref document: EP |